- Home
- ALGS
as 03-31-2025 12:30pm EST
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 38.8M | IPO Year: | 2020 |
| Target Price: | $70.00 | AVG Volume (30 days): | 154.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -20.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.76 - $46.80 | Next Earning Date: | 03-10-2025 |
| Revenue: | $3,945,000 | Revenue Growth: | -74.60% |
| Revenue Growth (this year): | -65.53% | Revenue Growth (next year): | N/A |
Latest Aligos Therapeutics Inc. News
ALGS Breaking Stock News: Dive into ALGS Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Aligos Therapeutics Presents Positive Data at APASL 2025
TipRanks
17 days ago
Biotech Alert: Searches spiking for these stocks today
GlobeNewswire
17 days ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
21 days ago
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
GlobeNewswire
21 days ago
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
a month ago
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
GlobeNewswire
2 months ago
Aligos Therapeutics Announces $105 Million Private Placement Financing
Simply Wall St.
2 months ago
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely
Compare ALGS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALGS Aligos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.